الانتقال إلى المحتوى الرئيسي
xMedica

NCT06909565ClinicalTrials.gov

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on…

المرحلة 4مطلوب 6,000 مشارك153 موقعاًدولة واحدة

الفئات

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2025-04-03; recorded start 2025-07-23
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 475 other studies in this databaseCounted from the lead sponsor named in the record (Duke University)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: other.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 4 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type10/10

    Mortality / MACE endpoint (hard clinical outcome)

  • Multi-centre8/8

    Multi-centre: 115 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 6,000 participants (target), run at 153 sites.

How this score is built
  • Enrolment36/40

    6,000 participants (target)

  • Site count23/25

    115 sites

  • Country count0/15

    Single country

  • Planned duration9/10

    Planned over about 53 months

  • Sponsor scale10/10

    Duke University has led 456 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.

CKJX839D1US04R is a pragmatic, randomized, double-blind, parallel group, placebo-controlled, multicenter, event-driven study evaluating inclisiran sodium 300 mg subcutaneous administered on Day 1, Month 3 (Day 90), and every 6 months thereafter in participants presenting for elective or urgent percutaneous coronary or peripheral endovascular intervention (PCI or PVI). At the time of a successful revascularization procedure or up to 14 days following the procedure, participants will be randomized and administered the first dose of inclisiran or corresponding placebo in a 1:1 fashion, stratified by the type of index arterial revascularization procedure, either coronary (i.e., PCI) or lower extremity (i.e., PV). The enrollment population will be representative of typical patients in the US with atherosclerotic cardiovascular disease, either coronary artery disease (CAD) or peripheral artery disease (PAD), and the trial endpoints are designed to be scientifically relevant and clinically meaningful to patients, clinicians, and other persons involved in the care of cardiovascular patients. The trial is designed to also understand how inclisiran therapy can be implemented in real-world clinical practice settings. The expected enrollment of the trial is approximately 6,000 participants, randomized in a 1:1 fashion to receive inclisiran or placebo, within 14 days of successful percutaneous coronary or lower extremity peripheral endovascular intervention for symptomatic atherosclerotic cardiovascular disease (ASCVD). Inclisiran sodium or corresponding placebo will be administered by s.c. injection to participants presenting for percutaneous coronary or peripheral endovascular intervention, in addition to usual care according to their individual medical history. All participants randomized to the treatment arm will receive inclisiran in addition to usual care per their regular physician direction, and those participants randomized to placebo will receive matching placebo, as well as usual care treatment, according to their treating physician. Study duration is determined by event accrual consistent with the event-driven design, i.e., when approximately 2380 primary composite events have occurred and at least 50% of participants have at least 36 months of follow-up. Assuming 18 months of recruitment at a uniform rate, the last patients enrolled will have about 27 months of follow-up. Therefore, study duration should be approximately 4 years. The study is event-driven, and thus, all participants will be treated (or followed in the case of permanent discontinuation of study drug) until the End of Study visit. As such, the planned duration of treatment cannot be stipulated for an individual participant. The estimated maximum treatment period for an individual participant is approximately 45 months, and the mean treatment duration is expected to be approximately 36 months.

الحالات

  • Percutaneous Coronary Intervention
  • Peripheral Endovascular Intervention

الأهلية

الأهلية
الجنسالجميع
الأعمار18 Years – لا حد أقصى
المتطوعون الأصحّاءلا

الأهلية كما كُتبت في السجل

Inclusion Criteria: * Signed informed consent must be obtained prior to participation in the study. * Males or females ≥ 18 years of age * Within 14 days of a successful percutaneous coronary intervention (PCI) or peripheral endovascular intervention (PVI) for symptomatic CAD or lower extremity PAD * Patients undergoing planned staged interventions are eligible for randomization only after the last planned intervention Exclusion Criteria: * Planned future PCI or PVI * Current or planned use of an open-label PCSK9 inhibitor during the study * Any prior treatment with inclisiran * Active or planned participation in another clinical study involving investigational drugs or devices during the study * Any serious liver disease, metabolic disease, neoplasm, end-stage kidney disease, or other condition in the opinion of the investigator that would inhibit trial participation or confound trial results * Any other reason why, in the opinion of the investigator, the participant would not be suitable for study participation including safety considerations and the ability to adhere to protocol activities * Patients taking prohibited therapies as listed in Section 6.6.3 * Pregnant or breast-feeding women

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

تصميم الدراسة
نوع الدراسةتدخّلية
المرحلةالمرحلة 4
التخصيصمعشّاة
نموذج التدخّلPARALLEL
الغرض الأساسيPREVENTION
التعميةQUADRUPLE (4)
التجنيدمطلوب 6,000 مشارك

الجهة الراعية والمتعاونون

  • Duke University الجهة الراعية
  • Novartis Pharmaceuticals المتعاونون
  • Colorado Prevention Center المتعاونون
  • Mount Sinai Hospital, New York المتعاونون

الأذرع والتدخلات

  • Inclisiran SodiumACTIVE_COMPARATOR

    Inclisiran sodium 300 mg subcutaneous injection

  • PlaceboPLACEBO_COMPARATOR

    Normal saline 1.5 ml subcutaneous injection

التدخلات

  • دواء Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

    300 mg (equivalent to 284 mg inclisiran) in 1.5 mL subcutaneous injection at Day 0; Day 90; \& every 6 months thereafter

  • دواء Normal Saline (Placebo)

    Normal saline placebo subcutaneous injection given at Day 0, Day 90; \& every 6 months thereafter

مقاييس النتائج

  1. مقياس النتيجة الأولي

    Total number of major adverse cardiovascular events (MACE) after coronary or peripheral endovascular revascularization

    MACEs include CHD death, non-fatal MI, ischemic stroke, ALI, major (above the ankle) amputation of vascular etiology, clinically driven coronary and limb revascularization.

    الإطار الزمني From randomization to first occurrence of MACE (up to approximately 4 years)

  2. مقياس النتيجة الأولي

    Total number of major adverse limb events (MALE) after endovascular revascularization

    MALEs consist of ALI, major amputation of vascular etiology, clinically driven lower extremity peripheral revascularization.

    الإطار الزمني From randomization to first occurrence of MALE (up to approximately 4 years)

  3. مقياس النتيجة الثانوي

    Number of participants with cardiovascular (CV) death

    الإطار الزمني From randomization to CV death (up to approximately 4 years)

  4. مقياس النتيجة الثانوي

    Number of participants with all cause death

    الإطار الزمني From randomization to all cause death (up to approximately 4 years)

  5. مقياس النتيجة الثانوي

    Number of participants with venous thromboembolic events (VTE)

    الإطار الزمني From randomization to first VTE (up to approximately 4 years)

التواريخ

التواريخ
تاريخ البدء23 يوليو 2025 (فعلي)
الإتمام الأولي1 أكتوبر 2029 (تقديري)
الإتمام1 ديسمبر 2029 (تقديري)
أول نشر3 أبريل 2025 (فعلي)
آخر تحديث16 نوفمبر 2026
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةيوليو 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

149 موقعاً قيد التجنيد

United States

United States
المنشأةالمدينةالولاية أو المنطقةالحالة
Capital Cardiology AssociatesAlbanyNew Yorkقيد التجنيد
Presbyterian Heart GroupAlbuquerqueNew Mexicoقيد التجنيد
Advanced Cardiovascular LLCAlexander CityAlabamaقيد التجنيد
Amarillo Heart Clinical Research Institute, Inc.AmarilloTexasقيد التجنيد
PharmaTex ResearchAmarilloTexasقيد التجنيد
AnMed Health Medical CenterAndersonSouth Carolinaقيد التجنيد
Asheville Cardiology Associates Research DepartmentAshevilleNorth Carolinaقيد التجنيد
University of Colorado Anschutz Medical CampusAuroraColoradoقيد التجنيد
Austin HeartAustinTexasقيد التجنيد
IMS CardiologyAvondaleArizonaقيد التجنيد
Northern Light Eastern Maine Medical CenterBangorMaineقيد التجنيد
St. Luke's University Health NetworkBethlehemPennsylvaniaقيد التجنيد
Pacific Oaks Medical GroupBeverly HillsCaliforniaقيد التجنيد
Cardiology, PCBirminghamAlabamaقيد التجنيد
Grace Research, LLCBossier CityLouisianaقيد التجنيد
Bridgeport HospitalBridgeportConnecticutقيد التجنيد
Advanced Heart Care LLCBridgewaterNew Jerseyقيد التجنيد
Trinity Medical WNY, PCBuffaloNew Yorkقيد التجنيد
Sisters of Charity HospitalBuffaloNew Yorkقيد التجنيد
Capital Area Research LLCCamp HillPennsylvaniaقيد التجنيد
Aultman HospitalCantonOhioقيد التجنيد
Wellspan Chambersburg HospitalChambersburgPennsylvaniaقيد التجنيد
Mecklenburg Heart SpecialistsCharlotteNorth Carolinaقيد التجنيد
Novant Health Clinical Research/Heart & Vascular InstituteCharlotteNorth Carolinaقيد التجنيد
Atrium Health-Sanger Heart and Vascular InstituteCharlotteNorth Carolinaقيد التجنيد
University of Illinois ChicagoChicagoIllinoisقيد التجنيد
Cardiovascular Institute of San DiegoChula VistaCaliforniaقيد التجنيد
Clearwater Cardiovascular ConsultantsClearwaterFloridaقيد التجنيد
BayCare Medical GroupClearwaterFloridaقيد التجنيد
MedStar Southern Maryland Hospital CenterClintonMarylandقيد التجنيد
University of Missouri Health CareColumbiaMissouriقيد التجنيد
John Muir Medical Center - Concord CampusConcordCaliforniaقيد التجنيد
Javara inc.ConroeTexasمسحوب
Pioneer Clinical StudiesCoral GablesFloridaقيد التجنيد
Valley Clinical TrialsCovinaCaliforniaمسحوب
Louisiana Heart CenterCovingtonLouisianaقيد التجنيد
Nuvance Health- Danbury HospitalDanburyConnecticutقيد التجنيد
Cardiology Research AssociatesDaytona BeachFloridaقيد التجنيد
Arrow Clinical TrailsDaytona BeachFloridaقيد التجنيد
Essentia Health-SMMCDuluthMinnesotaقيد التجنيد
Aspirus Saint Luke's HospitalDuluthMinnesotaقيد التجنيد
Midwest Cardiovascular Research and Education FoundationElkhartIndianaقيد التجنيد
Cardiovascular Associates of the Delaware ValleyElmerNew Jerseyقيد التجنيد
Aurora Denver Cardiology Associates - EnglewoodEnglewoodColoradoقيد التجنيد
Javara Inc.FayettevilleNorth Carolinaقيد التجنيد
Advanced Heart and Vascular Institute Of HunterdonFlemingtonNew Jerseyقيد التجنيد
Northeast Georgia Heart Center, PCGainesvilleGeorgiaقيد التجنيد
Stern Cardiovascular CenterGermantownTennesseeقيد التجنيد
Thrive Clinical Research GroupGlendoraCaliforniaقيد التجنيد
CHI Health Nebraska HeartGrand IslandNebraskaقيد التجنيد

تُدرَج 103 مواقع إضافية في سجل السجل.

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

  1. 16 نوفمبر 2026

    أُضيف موقع

    4 sites added (153 total)

    149153

  2. 29 أكتوبر 2026

    أُضيف موقع

    2 sites added (149 total)

    147149

  3. 23 أكتوبر 2026

    أُضيف موقع

    2 sites added (147 total)

    145147

  4. 19 أكتوبر 2026

    أُضيف موقع

    3 sites added (145 total)

    142145

  5. 5 أكتوبر 2026

    أُضيف موقع

    1 site added (142 total)

    141142

  6. 28 سبتمبر 2026

    أُضيف موقع

    2 sites added (141 total)

    139141

  7. 22 سبتمبر 2026

    أُضيف موقع

    1 site added (139 total)

    138139

  8. 15 سبتمبر 2026

    أُضيف موقع

    2 sites added (138 total)

    136138

  9. 28 أغسطس 2026

    أُضيف موقع

    3 sites added (136 total)

    133136

  10. 18 أغسطس 2026

    أُضيف موقع

    8 sites added (133 total)

    125133

  11. 5 أغسطس 2026

    أُضيف موقع

    10 sites added (125 total)

    115125